Category: 2023

Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer C

Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PH. (2023) Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front. Immunol. 2023 Sep 6:14:1188831

Read on
Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity D

Albert BA, Yang Y, Shao XM, Singh D, Smith KN, Anagnostou V, Karchin R Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity (2023) Nat Mach Intell. https://doi.org/10.1038/s42256-023-00694-6

Read on
Persistent mutation burden drives sustained anti-tumor immune responses P

Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. (2023) Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. Feb;29(2):440-449

Read on
Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy C

Gong X, Karchin R (2023) Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy Sci Rep. Jan 18;13(1):950

Read on